Clinical evaluation of melasma (Jhaain) with Unani drug
Phase 2
- Conditions
- Health Condition 1: L811- Chloasma
- Registration Number
- CTRI/2021/03/032310
- Lead Sponsor
- uqman Unani Medical College Hospital and Research Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Clinically diagnosed patients of bilateral facial Kalaf and confirmed by dermoscope
-Epidermal and mixed melasma based on dermoscope
Exclusion Criteria
-Already diagnose systematic and skin allergic diseases
-Skin sensitivity 1-4 type by Fitzpatrick skin type
-Pregnant and lactating women
-Hypersensitivity reaction to Hydroquinone
-Use of Hydroquinone and other anti-tyrosinase drugs within 3 months from baseline
-History of chemical peels and facial laser treatment within 9 months and use of sun protector creams
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in mMASI(Modified Melasma Area Severity Index)Timepoint: Baseline, 2nd week, 4th week, 6th week, 8th week
- Secondary Outcome Measures
Name Time Method Change in Investigatorâ??s Global Assessment For Melasma Severity on 100mm VAS. <br/ ><br>Change in Patientâ??s Global Assessment (PtGA). <br/ ><br>Change in Dermatology Life Quality Index (DLQI)Timepoint: Baseline, 2nd week, 4th week, 6th week, 8th week